Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.104 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.198NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
EG.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XAFNNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BC.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
P.1.17.1 (Gamma)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.3.16NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.177.41NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.375NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BL.1.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.99NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBF.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.343NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.4.17 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.25.1.2 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.409NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.83NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.310NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.362.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.162NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
Y.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.86NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.154NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.4.8NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
A.2.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.41NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.137NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.446NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.76 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.398NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.163NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
P.3 (Theta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.38.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XAVNNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BE.1.4.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBC.1.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BM.4.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BF.20NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.77NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.60NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.9.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.11NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.3.15NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.5.6.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.5.1.35NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.1.45NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.177.31NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.39.1.2 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.4.15 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.75.10NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used